Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Merckle GmbH ) Identifier:
First received: April 18, 2012
Last updated: May 17, 2016
Last verified: May 2016
This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma scheduled to receive chemotherapy (CTX)

Condition Intervention Phase
Ewing Family of Tumors, Rhabdomyosarcoma
Drug: Lipegfilgrastim
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • PK: Area under the curve, Maximum observed serum concentration (Cmax), Rate constant associated with terminal phase, Mean Residence Time, Time to reach Cmax, and Apparent volume of distribution during terminal phase after non-intravenous administration [ Time Frame: 16 months ]
    A total of 7 PK samples will be obtained at prespecified periods

Secondary Outcome Measures:
  • PD:Absolute Neutrophil Count [ Time Frame: 16 months ]

Enrollment: 21
Study Start Date: July 2012
Study Completion Date: April 2015
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: XM22, 100 μg/kg BW Drug: Lipegfilgrastim
Lipegfilgrastim 100ug/kg


Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female children and adolescents aged 2 to <18 years
  • Written informed consent provided by parent(s)/legal representative(s) of the pediatric patient and patient's assent if appropriate
  • Able to understand and/or follow study instructions alone or with parental assistance
  • Diagnosed with the Ewing family of tumors or Rhabdomyosarcoma
  • Scheduled to receive 1 of the following CTX regimens (inpatient or outpatient)
  • For the Ewing family of tumors:

    • vincristine/ifosfamide/doxorubicin/etoposide (VIDE); with concomitant sodium 2-mercaptoethane sulfonate (MESNA) according to local standards
    • vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
  • For rhabdomyosarcoma:

    • vincristine/actinomycin/cyclophosphamide (VAC)
    • vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
  • Chemotherapy-naïve
  • Body weight ≥15 kg
  • White blood cell (WBC) count >2.5 x 109/L, absolute neutrophil count (ANC) ≥1.5 x 109/L, and platelet count ≥100 x 109/L (at screening and prior to CTX)
  • For patients aged ≥12 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (See Appendix A.)
  • Fertile patients (male or female) must use highly reliable contraceptive measures (i.e. two of the following: oral contraception, implants, injections, barrier contraception, and intrauterine device, or vasectomized/sterilized partners, or sexual abstinence). For purposes of this study, a fertile female patient is any female patient who has experienced menarche and who has not undergone tubal ligation.
  • Female patients who have attained menarche must have a negative urine pregnancy test at the screening visit.

Exclusion Criteria:

  • Previous exposure to filgrastim, pegfilgrastim or lenograstim or other G-CSFs in clinical development within 6 months prior to the XM22 administration
  • Known hypersensitivity to filgrastim, pegfilgrastim or lenograstim or any other G-CSF in clinical development
  • History of congenital neutropenia or cyclic neutropenia
  • Any illness or condition that in the opinion of the Investigator may affect the safety of the patient or the evaluation of any study endpoint
  • Pregnant or nursing women
  • Fertile patients who do not agree to use highly reliable contraceptive measures during the entire duration of the study
  • Prior bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow (e.g. whole pelvic radiation) for any reason, or any therapeutic radiation within the 3 weeks prior to the XM22 dose
  • Ongoing active infection or history of infectious disease within 2 weeks prior to the screening visit
  • Treatment with lithium at screening or planned during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01585649

Teva Investigational Site 0103
Plovdiv, Bulgaria
Teva Investigational Site 0101
Sofia, Bulgaria
Teva Investigational Site 0102
Varna, Bulgaria
Czech Republic
Teva Investigational Site 0201
Praha 5, Czech Republic
Teva Investigational Site 0301
Budapest, Hungary
Teva Investigational Site 0401
Lublin, Poland
Russian Federation
Teva Investigational Site 0501
Chelyabinsk, Russian Federation
Teva Investigational Site 0504
Ekaterinburg, Russian Federation
Teva Investigational Site 0507
Krasnodar, Russian Federation
Teva Investigational Site 0505
Moscow, Russian Federation
Teva Investigational Site 0506
Moscow, Russian Federation
Teva Investigational Site 0508
Moscow, Russian Federation
Teva Investigational Site 0502
St. Petersburg, Russian Federation
Teva Investigational Site 0701
Dnipropetrovsk, Ukraine
Teva Investigational Site 0705
Donetsk, Ukraine
Teva Investigational Site 0702
Kharkiv, Ukraine
Teva Investigational Site 0704
Kyiv, Ukraine
Teva Investigational Site 0703
Lviv, Ukraine
Sponsors and Collaborators
Merckle GmbH
Study Director: Andreas Lammerich, MD Merckle GmbH, Teva Ratiopharm
  More Information

Responsible Party: Merckle GmbH Identifier: NCT01585649     History of Changes
Other Study ID Numbers: XM22-07
2011-004742-18 ( EudraCT Number )
Study First Received: April 18, 2012
Last Updated: May 17, 2016

Additional relevant MeSH terms:
Sarcoma, Ewing
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue processed this record on May 25, 2017